The ImClone stock trading scandal is a notable case of insider trading that shook the financial world in the early 2000s. It involved high-profile figures such as Samuel Waksal, the founder of ImClone Systems, and Martha Stewart, a well-known media personality. This article provides a timeline of the events that led to the scandal and its aftermath, highlighting the key moments that defined this case.
The Rise and Fall of ImClone Systems
ImClone Systems was founded in 1984 and quickly
became a prominent player in the biopharmaceutical industry, focusing on developing biologic medicines for oncology. The company's fortunes soared when it developed Erbitux, a promising cancer drug. In September 2001, Bristol-Myers Squibb signed a $2 billion deal with ImClone for the marketing rights to Erbitux, reflecting the drug's blockbuster potential.
However, the tide turned in December 2001 when the FDA issued a Refuse to File decision, rejecting ImClone's application due to concerns about the clinical trials' structure. This decision was a significant blow to the company, causing its stock price to plummet.
Insider Trading Unveiled
The scandal began to unfold when it was revealed that Samuel Waksal had tipped off friends and family to sell their ImClone stock before the FDA's decision was publicly announced. On December 27, 2001, Waksal's daughter sold $2.5 million in shares, and his father sold $8.1 million over the next two days. Other company executives followed suit, selling millions in shares.
Martha Stewart also became embroiled in the scandal when she sold about $230,000 in ImClone shares on December 27, 2001, after receiving nonpublic information from her broker, Peter Bacanovic. This sale allowed her to avoid a significant loss when the stock value fell 16% the following day.
Legal Consequences and Aftermath
The legal repercussions were swift. Samuel Waksal was arrested in 2002 and later pleaded guilty to securities fraud, receiving a sentence of seven years and three months in prison. Martha Stewart was indicted on charges of obstruction of justice and conspiracy, leading to a five-month prison sentence, five months of home confinement, and two years of probation.
Despite the scandal, Erbitux eventually received FDA approval in 2004 for use in colon cancer treatment. ImClone Systems was acquired by Eli Lilly and Company in 2008, marking the end of its independent operations. The scandal remains a cautionary tale about the consequences of insider trading and the importance of ethical conduct in business.
